Anzeige
Mehr »
Login
Montag, 07.10.2024 Börsentäglich über 12.000 News von 690 internationalen Medien
Aktie mit Joker-Assets: Der Schlüssel zur Lösung des globalen Kupfermangels
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
135 Leser
Artikel bewerten:
(0)

Brainomix; Visionable: Visionable and Brainomix announce strategic partnership to tackle "bottlenecks" in time-sensitive stroke care pathway

  • Benefits of combining Visionable's virtual platform with Brainomix's e-Stroke imaging already demonstrated at Ipswich Hospital

KENT, England and OXFORD, England, Nov. 10, 2022 /PRNewswire/ -- Visionable, a real-time clinical collaboration platform enabling virtual healthcare models, and Brainomix, an AI-powered medtech solutions company, have announced a powerful strategic partnership that is transforming the delivery of stroke care.

Visionable's Connected Healthcare Centre, Kent UK. Copyright: Visionable

The two tech-enabled health companies have partnered to collaborate and co-market two complementary solutions through Visionable's collaboration platform and Brainomix's e-Stroke AI software to enhance stroke care delivery across the end-to-end pathway, from pre-acute to the intra-hospital.

Visionable's unique, patented, next-generation digital healthcare collaboration platform can be used across the care pathway, from emergency response connecting front-line responders and members of public on scene to remote specialist clinicians, through to hospital treatment, including virtual consultations, multidisciplinary team (MDT) meetings and at-home care.

This platform is combined with Brainomix's e-Stroke software - a collection of tools that use state-of-the-art AI algorithms to support doctors by providing real-time interpretation of brain scans to help guide treatment and transfer decisions for stroke patients, allowing more patients to be treated in the right place, at the right time.

The two complementary technologies are saving time, reducing workload, and supporting improved outcomes which aligns with the UK national strategy to drive integration and efficiency for better care.

Brainomix is a recipient of a prestigious NHS Artificial Intelligence in Health and Care Award under which it has been deploying e-Stroke across a number of UK stroke networks over the past two years to evaluate its impact on stroke care across NHS regions. The additional benefit of combining e-Stroke with Visionable's platform has been pioneered by the stroke team at Ipswich Hospital in Suffolk, with patients and staff already reaping positive results through faster delivery of care, superior performance metrics, and, most importantly, improved patient outcomes.

Lynda Sibson, Telemedicine Manager, East of England Stroke Telemedicine Partnership, works across the region to support the transformation of stroke care through the adoption of innovative digital tools. She played a central role in introducing the two solutions to Ipswich Hospital. Commenting on the value that Visionable and Brainomix are delivering, she said: "Both systems are easy and intuitive to operate, and highly complementary, ensuring timely sharing of clinical and radiological information that ultimately enables faster patient transfers. The companies are true partners, easy to work with and highly responsive. We have also found that the technologies are affording our clinicians more flexibility and an improved work-life balance - not something to be underestimated!"

Dr Sajid Alam, Stroke Consultant at Ipswich Hospital, said: "As a district general hospital, we don't have ready access to dedicated neuroradiologists to interpret every stroke scan. Having the AI software gives us more confidence when interpreting each scan - particularly the CTA's, where we look for a large vessel occlusion (LVO), a key indicator of patient eligibility for mechanical thrombectomy."

Patients admitted to Ipswich Hospital who are eligible for mechanical thrombectomy are transferred to the Royal London Hospital (RLH), a comprehensive stroke centre in Whitechapel that serves as a supraregional thrombectomy hub for Ipswich and a number of other stroke units across the Southeast of England.

Dr Alam added: "In stroke, time is critical. Using e-Stroke saves precious minutes, as the scans are immediately available for viewing on the Brainomix web portal. With RLH also using e-Stroke, we can communicate instantly, share images and make transfer decisions without delay."

Recent performance metrics indicate that Ipswich Hospital is delivering best in-class service, with the proportion of patients being assessed by a Stroke Consultant within 24 hours above the national average (90.4% vs 82.9%), along with how quickly that assessment takes place from admission (4 hours 20 minutes compared to 9 hours 53 minutes nationally).

This partnership is the latest in a series of collaborations that Visionable has brokered with partner health tech organisations that offer complementary services that enhance the delivery of care. Rob Hughes, Chief Commercial Officer at Visionable, said: "Technology must make life easier for clinicians and improve treatment for patients; Brainomix and Visionable are delivering value in both areas. Combined, our complementary solutions have resulted in quicker delivery of care, instant access to rich data and improved patient outcomes - all while boosting job satisfaction for clinicians. The success so far is exciting, and we look forward to the growing impact our partnership will have on the quality of care for stroke patients."

Riaz Rahman, VP Healthcare Global at Brainomix, added: "The strength of combining the proven technologies of Visionable and Brainomix means easy and instantaneous access to rich critical clinical information across the pre-acute and intra-hospital phases of stroke care. Our joint approach will tackle head on many of the known systems bottlenecks where multiple stroke centres are involved in a highly time sensitive pathway. We are excited by the enhanced efficiency and value our partnership will bring to healthcare professionals and our customers and look forward to accelerating the adoption of our combined systems under our partnership."

About Visionable

Visionable is helping make connected healthcare a reality in the UK and around the world. Driven by the belief that affordable, high-quality, timely healthcare is a basic human right that should be accessible to all, Visionable have created their own proprietary clinical collaboration platform. This enables the hospital to come to the patient and for healthcare teams to collaborate freely across multiple locations.

To learn more about Visionable and its technology visit visionable.com, and follow us on Twitter, LinkedIn, Vimeo and Instagram.

About Brainomix

Brainomix specializes in the creation of AI-powered software solutions to enable precision medicine for better treatment decisions in stroke, lung fibrosis, and cancer. With origins as a spin-out from the University of Oxford, Brainomix is an expanding commercial-stage company that has innovated award-winning imaging biomarkers and software solutions that are used in more than 30 countries worldwide. Its first product, the e-Stroke platform, provides clinicians with the most comprehensive stroke imaging solution, driving faster treatment times and improving functional independence for patients. Its pipeline includes novel imaging biomarkers for better treatment of lung fibrosis and cancer, and its technology is being used by pharmaceutical companies to improve clinical trial success.

A private company, with headquarters in Oxford, UK Brainomix's investors include Boehringer Ingelheim Venture Fund, Parkwalk Advisors, Tencent Holdings and Oxford University Innovation Fund.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn and Facebook.

Contacts:

Visionable
Vaishali Patel, Head of Marketing, UK
vpatel@visionable.com
T +44 (0) 20 3519 0953

Media enquiries (for Visionable)
Ellie Gadd, Senior Account Manager, Silver Buck
ellie@silver-buck.com
M +44 (0)7450 472313

Brainomix
Jeff Wyrtzen, Chief Marketing & Business Development Officer
jwyrtzen@brainomix.com
M +44 (0)7927 164210
T +44 (0)1865 582730

Media enquiries (for Brainomix)
Sue Charles, Charles Consultants
Sue@charles-consultants.com
M +44 (0)7968 726585

Photo - https://mma.prnewswire.com/media/1943943/Visionable.jpg
Logo - https://mma.prnewswire.com/media/1942970/Brainomix_Logo.jpg
Logo - https://mma.prnewswire.com/media/1942964/Visionable_Logo.jpg

Brainomix Logo

Visionable Logo

Cision View original content:https://www.prnewswire.co.uk/news-releases/visionable-and-brainomix-announce-strategic-partnership-to-tackle-bottlenecks-in-time-sensitive-stroke-care-pathway-301673607.html

© 2022 PR Newswire
Sondersituation: Vervielfachungschance bei diesen Goldaktien

Der Goldpreis haussiert und schwingt sich von Hoch zu Hoch. Getrieben von geopolitischen Unsicherheiten sowie der Aussicht auf eine lockere Geldpolitik der FED gehen Experten aktuell von weiter steigenden Notierungen bis sogar in den Bereich von 3.000 US-Dollar je Unze Gold aus.

Im Schatten des Basispreises notieren Goldproduzenten aus der zweiten Reihe sowie Explorationsunternehmen noch weit weg von ihren historischen Höchstständen entfernt und bieten dadurch erhebliches Aufholpotential.

In diesem kostenlosen Report geben wir Ihnen Favoriten an die Hand, die aufgrund von Sondersituation die Chance auf eine Kursvervielfachung besitzen.

Handeln Sie Jetzt!

Fordern Sie jetzt den brandneuen Spezialreport an und profitieren Sie von dem weiter steigenden Kurs des Edelmetalls.

Sichern Sie sich jetzt Ihren kostenfreien Report.

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.